Skip to content

Study · Animal study (in vivo) · mouse · 2014

15 results

Activation of growth hormone secretagogue receptor induces time-dependent clock phase delay in mice.

Zhou L, Gao Q, Zhang P, Guo S, Gu J, Hao W, Cao JM

American journal of physiology. Endocrinology and metabolism29 Jul 2014Cited by 6 (Europe PMC)

PMID25074983 (opens in a new tab)DOI10.1152/ajpendo.00535.2013 (opens in a new tab)PepBankPUB-25074983
Publisher pagePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In male mice under constant darkness, GHRP‑6 at CT12 delayed free-running locomotor rhythms.

    In plain wordsIn mice under constant darkness, GHRP‑6 at CT12 delayed the timing of locomotor rhythms.

    Peptide
    GHRP-6
    Outcome
    MixedLocomotor circadian phase at CT12
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Sleep · Sleep
    Studied dose
    100 μg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    The results showed that bolus administration of GHRP-6 (100 μg/kg ip) at the beginning of subjective night (CT12) induced a phase delay of the free-running rhythms in male C57BL/6J mice under constant darkness, but did not elicit phase shift at other checked circadian time (CT) points.
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In male mice under constant darkness, GHRP‑6 did not shift locomotor circadian phase at the other tested circadian times.

    In plain wordsIn mice under constant darkness, GHRP‑6 did not shift locomotor rhythm timing at other tested circadian times.

    Peptide
    GHRP-6
    Outcome
    No significant changeLocomotor phase at other tested circadian times
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Sleep · Sleep
    Studied dose
    100 μg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    The results showed that bolus administration of GHRP-6 (100 μg/kg ip) at the beginning of subjective night (CT12) induced a phase delay of the free-running rhythms in male C57BL/6J mice under constant darkness, but did not elicit phase shift at other checked circadian time (CT) points.
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice, GHRP‑6 at CT12 induced greater SCN calcium mobilization than at CT6.

    In plain wordsIn mice, GHRP‑6 increased SCN calcium mobilization more at CT12 than at CT6.

    Peptide
    GHRP-6
    Outcome
    IncreaseSCN calcium mobilization
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Comparator
    GHRP-6 at CT6
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Further analyses demonstrated that GHRP-6 at CT12 induced higher calcium mobilization and neuronal discharge in the SCN compared with that at CT6
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice, GHRP‑6 at CT12 induced greater SCN neuronal discharge than at CT6.

    In plain wordsIn mice, GHRP‑6 increased SCN nerve activity more at CT12 than at CT6.

    Peptide
    GHRP-6
    Outcome
    IncreaseSCN neuronal discharge
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Comparator
    GHRP-6 at CT6
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Further analyses demonstrated that GHRP-6 at CT12 induced higher calcium mobilization and neuronal discharge in the SCN compared with that at CT6
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice, GHRP‑6 at CT12 decreased SCN glutamate levels.

    In plain wordsIn mice, GHRP‑6 at CT12 decreased glutamate levels in the SCN.

    Peptide
    GHRP-6
    Outcome
    DecreaseSCN glutamate levels
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    decreased the levels of glutamate and γ-aminobutyric acid
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice, GHRP‑6 at CT12 decreased SCN gamma-aminobutyric acid levels.

    In plain wordsIn mice, GHRP‑6 at CT12 decreased gamma-aminobutyric acid levels in the SCN.

    Peptide
    GHRP-6
    Outcome
    DecreaseSCN gamma-aminobutyric acid levels
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    decreased the levels of glutamate and γ-aminobutyric acid
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice, GHRP‑6 at CT12 increased SCN phosphorylated CaMKII levels.

    In plain wordsIn mice, GHRP‑6 at CT12 increased phosphorylated CaMKII levels in the SCN.

    Peptide
    GHRP-6
    Outcome
    IncreaseSCN phosphorylated CaMKII levels
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    increased the levels of p-CaMKII, p-CREB, and period 1
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In mice, GHRP‑6 at CT12 increased SCN phosphorylated CREB levels.

    In plain wordsIn mice, GHRP‑6 at CT12 increased phosphorylated CREB levels in the SCN.

    Peptide
    GHRP-6
    Outcome
    IncreaseSCN phosphorylated CREB levels
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    increased the levels of p-CaMKII, p-CREB, and period 1
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In mice, GHRP‑6 at CT12 increased SCN period 1 levels.

    In plain wordsIn mice, GHRP‑6 at CT12 increased period 1 levels in the SCN.

    Peptide
    GHRP-6
    Outcome
    IncreaseSCN period 1 levels
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    increased the levels of p-CaMKII, p-CREB, and period 1
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In mice, GHRP‑6 at CT12 delayed circadian expression of circadian locomotor output cycles kaput in the SCN.

    In plain wordsIn mice, GHRP‑6 at CT12 delayed Clock gene expression rhythms in the SCN.

    Peptide
    GHRP-6
    Outcome
    MixedClock circadian expression timing
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and delayed the circadian expressions of circadian locomotor output cycles kaput, Bmal1, and prokineticin 2 in the SCN
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In mice, GHRP‑6 at CT12 delayed circadian Bmal1 expression in the SCN.

    In plain wordsIn mice, GHRP‑6 at CT12 delayed Bmal1 expression rhythms in the SCN.

    Peptide
    GHRP-6
    Outcome
    MixedBmal1 circadian expression timing
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and delayed the circadian expressions of circadian locomotor output cycles kaput, Bmal1, and prokineticin 2 in the SCN
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In mice, GHRP‑6 at CT12 delayed circadian prokineticin 2 expression in the SCN.

    In plain wordsIn mice, GHRP‑6 at CT12 delayed prokineticin 2 expression rhythms in the SCN.

    Peptide
    GHRP-6
    Outcome
    MixedProkineticin 2 circadian expression timing
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and delayed the circadian expressions of circadian locomotor output cycles kaput, Bmal1, and prokineticin 2 in the SCN
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.

Studies that did not test the peptide alone3

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 13AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In mice, d-(+)-Lys-GHRP‑6 abolished the circadian phase delay induced by GHRP‑6.

    In plain wordsIn mice, d-(+)-Lys-GHRP‑6 blocked the timing delay seen with GHRP‑6 alone.

    Peptide
    GHRP-6
    Outcome
    DecreasePhase delay with GHS receptor antagonist
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Comparator
    GHRP-6 alone
    Outcome group
    Sleep · Sleep

    Source sentences

    Summary
    The phase-delay effect of GHRP-6 was abolished by d-(+)-Lys-GHRP-6 (GHS receptor antagonist), KN-93 [calcium/calmodulin-dependent protein kinase II (CaMK) II inhibitor], or anti-phosphorylated (p)-cAMP response element-binding protein (CREB) antibody.
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 14AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In mice, KN-93 abolished the circadian phase delay induced by GHRP‑6.

    In plain wordsIn mice, KN-93 blocked the timing delay seen with GHRP‑6 alone.

    Peptide
    GHRP-6
    Outcome
    DecreasePhase delay with CaMKII inhibitor
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Comparator
    GHRP-6 alone
    Outcome group
    Sleep · Sleep

    Source sentences

    Summary
    The phase-delay effect of GHRP-6 was abolished by d-(+)-Lys-GHRP-6 (GHS receptor antagonist), KN-93 [calcium/calmodulin-dependent protein kinase II (CaMK) II inhibitor], or anti-phosphorylated (p)-cAMP response element-binding protein (CREB) antibody.
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 15AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In mice, anti-phosphorylated CREB antibody abolished the circadian phase delay induced by GHRP‑6.

    In plain wordsIn mice, an antibody against phosphorylated CREB blocked the timing delay seen with GHRP‑6 alone.

    Peptide
    GHRP-6
    Outcome
    DecreasePhase delay with anti-p-CREB antibody
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Comparator
    GHRP-6 alone
    Outcome group
    Sleep · Sleep

    Source sentences

    Summary
    The phase-delay effect of GHRP-6 was abolished by d-(+)-Lys-GHRP-6 (GHS receptor antagonist), KN-93 [calcium/calmodulin-dependent protein kinase II (CaMK) II inhibitor], or anti-phosphorylated (p)-cAMP response element-binding protein (CREB) antibody.
    1 context sentence
    Summary · context
    We examined the response of the hypothalamic suprachiasmatic nuclei (SCN) to growth hormone releasing peptide-6 (GHRP-6) by assessing effects on the phase of locomotor activity rhythms, SCN neuronal discharges, and the potential signaling pathways involved in the drug action on circadian rhythms.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.